104 related articles for article (PubMed ID: 16250842)
1. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.
Churcher I; Beher D
Curr Pharm Des; 2005; 11(26):3363-82. PubMed ID: 16250842
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
Beher D; Graham SL
Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
[TBL] [Abstract][Full Text] [Related]
3. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
4. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
5. Gamma-secretase inhibition.
Beher D; Shearman MS
Biochem Soc Trans; 2002 Aug; 30(4):534-7. PubMed ID: 12196131
[TBL] [Abstract][Full Text] [Related]
6. Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors.
Weihofen A; Lemberg MK; Friedmann E; Rueeger H; Schmitz A; Paganetti P; Rovelli G; Martoglio B
J Biol Chem; 2003 May; 278(19):16528-33. PubMed ID: 12621027
[TBL] [Abstract][Full Text] [Related]
7. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
8. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
9. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
10. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S
Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442
[TBL] [Abstract][Full Text] [Related]
11. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
12. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease.
Wolfe MS; Xia W; Moore CL; Leatherwood DD; Ostaszewski B; Rahmati T; Donkor IO; Selkoe DJ
Biochemistry; 1999 Apr; 38(15):4720-7. PubMed ID: 10200159
[TBL] [Abstract][Full Text] [Related]
13. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
15. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
[TBL] [Abstract][Full Text] [Related]
16. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the development of gamma-secretase inhibitors.
Josien H
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
[TBL] [Abstract][Full Text] [Related]
18. A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.
Teng L; Zhao J; Wang F; Ma L; Pei G
Cell Res; 2010 Feb; 20(2):138-53. PubMed ID: 20066010
[TBL] [Abstract][Full Text] [Related]
19. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease.
Tomita T; Iwatsubo T
Curr Pharm Des; 2006; 12(6):661-70. PubMed ID: 16472155
[TBL] [Abstract][Full Text] [Related]
20. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
